BE2013C051I2 - - Google Patents
Info
- Publication number
- BE2013C051I2 BE2013C051I2 BE2013C051C BE2013C051C BE2013C051I2 BE 2013C051 I2 BE2013C051 I2 BE 2013C051I2 BE 2013C051 C BE2013C051 C BE 2013C051C BE 2013C051 C BE2013C051 C BE 2013C051C BE 2013C051 I2 BE2013C051 I2 BE 2013C051I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26185299 | 1999-09-16 | ||
JP2000130371 | 2000-04-28 | ||
PCT/JP2000/006258 WO2001019802A1 (fr) | 1999-09-16 | 2000-09-13 | Composes cycliques aromatiques azotes a six elements |
EP00960979A EP1219609B1 (en) | 1999-09-16 | 2000-09-13 | Aromatic nitrogenous six-membered ring compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2013C051I2 true BE2013C051I2 (nl) | 2019-10-16 |
Family
ID=26545273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2013C051C BE2013C051I2 (nl) | 1999-09-16 | 2013-07-22 |
Country Status (27)
Country | Link |
---|---|
US (2) | US6656935B2 (nl) |
EP (1) | EP1219609B1 (nl) |
KR (1) | KR100532546B1 (nl) |
CN (2) | CN1374953A (nl) |
AR (1) | AR025668A1 (nl) |
AT (1) | ATE358670T1 (nl) |
AU (1) | AU767558B2 (nl) |
BE (1) | BE2013C051I2 (nl) |
BG (1) | BG65453B1 (nl) |
BR (1) | BRPI0014526C1 (nl) |
CA (1) | CA2383466C (nl) |
CY (2) | CY1106534T1 (nl) |
DE (1) | DE60034239T2 (nl) |
DK (1) | DK1219609T3 (nl) |
ES (1) | ES2283315T3 (nl) |
FR (1) | FR13C0050I2 (nl) |
HK (1) | HK1044535A1 (nl) |
HU (1) | HU225917B1 (nl) |
IL (2) | IL148291A0 (nl) |
LU (1) | LU92249I2 (nl) |
MY (1) | MY123528A (nl) |
NO (2) | NO322038B1 (nl) |
PT (1) | PT1219609E (nl) |
RU (1) | RU2233273C3 (nl) |
TR (1) | TR200200701T2 (nl) |
TW (1) | TWI258471B (nl) |
WO (1) | WO2001019802A1 (nl) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403597B1 (en) * | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US20080027037A1 (en) * | 2000-04-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Cyclic compounds |
US7273868B2 (en) * | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
CN1657523A (zh) * | 2000-04-28 | 2005-08-24 | 田边制药株式会社 | 环状化合物 |
ATE552013T1 (de) * | 2000-09-06 | 2012-04-15 | Mitsubishi Tanabe Pharma Corp | Zubereitungen zur oralen anwendung |
CA2423050A1 (en) * | 2000-09-20 | 2002-03-28 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazine derivatives as modulators of tyrosine kinases |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
US20020147198A1 (en) * | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
CA2437754C (en) | 2001-02-15 | 2010-05-18 | Tanabe Seiyaku Co., Ltd. | Tablets quickly disintegrated in oral cavity |
AR036375A1 (es) * | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
WO2003032997A1 (de) * | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
US6936629B2 (en) * | 2001-12-21 | 2005-08-30 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
US6924290B2 (en) * | 2002-01-23 | 2005-08-02 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
US7176310B1 (en) * | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
CA2485148A1 (en) * | 2002-05-09 | 2003-11-20 | Cytokinetics, Inc. | Pyrimidinone compounds, compositions and methods |
WO2003101994A1 (en) * | 2002-05-29 | 2003-12-11 | Abbott Laboratories | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction |
US7057042B2 (en) | 2002-05-29 | 2006-06-06 | Abbott Laboratories | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction |
AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
WO2004050610A2 (en) * | 2002-12-04 | 2004-06-17 | Gene Logic Inc. | Modulators of melanocortin receptor |
AP2006003771A0 (en) * | 2004-04-30 | 2006-10-31 | Warner Lambert Co | Substituted morpholine compounds for the treatmentof central nervous system disorders |
GB0409744D0 (en) * | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
MX2007012711A (es) | 2005-04-19 | 2008-01-11 | Nycomed Gmbh | Roflumilast para el tratamiento de hipertension pulmonar. |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
US8247556B2 (en) | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20080051413A1 (en) * | 2006-08-25 | 2008-02-28 | Kaohsiung Medical University | Nitrophenylpiperazine derivative of xanthine which relaxes tracheal airway and increases respiratory performance |
BRPI0716134A2 (pt) | 2006-09-07 | 2013-09-17 | Nycomed Gmbh | tratamento de combinaÇço para diabetes mellitus |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
TW200914457A (en) * | 2007-05-31 | 2009-04-01 | Kyowa Hakko Kogyo Kk | Pyrimidodiazepinone derivative |
KR101560844B1 (ko) | 2007-06-04 | 2015-10-15 | 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 | 트라이-아릴계 화합물 및 이를 포함하는 조성물 |
US8071557B2 (en) | 2007-06-13 | 2011-12-06 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors |
WO2009013286A1 (en) * | 2007-07-24 | 2009-01-29 | Novartis Ag | Organic compounds |
EP2202228B1 (en) * | 2007-10-15 | 2014-12-10 | Takeda Pharmaceutical Company Limited | Amide compounds and use of the same |
EP2082766A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Blister Strip Coil Forming |
EP2082767A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
EP2082771A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
EP2082772A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
EP2082768A1 (en) | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
CA2718528C (en) * | 2008-03-18 | 2016-10-25 | Merck Sharp & Dohme Corp. | Substituted 4-hydroxypyrimidine-5-carboxamides |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
WO2010144647A1 (en) | 2009-06-12 | 2010-12-16 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
US8354593B2 (en) * | 2009-07-10 | 2013-01-15 | Nanocomp Technologies, Inc. | Hybrid conductors and method of making same |
GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
EP2361911A1 (en) * | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
EP2361912A1 (en) * | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
KR101377178B1 (ko) | 2010-04-05 | 2014-03-26 | 에스케이케미칼주식회사 | Pde5 억제제를 함유하는 피부 주름 개선용 조성물 |
CN101798301A (zh) * | 2010-04-13 | 2010-08-11 | 漆又毛 | 吡咯烷基嘧啶甲磺酰胺衍生物及制备方法 |
TW201210584A (en) | 2010-08-18 | 2012-03-16 | Alcon Res Ltd | Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma |
CN102372697A (zh) * | 2010-08-19 | 2012-03-14 | 山东轩竹医药科技有限公司 | 取代的嘧啶类化合物 |
EP2735567B1 (en) * | 2011-07-21 | 2016-10-26 | Xuanzhu Pharma Co., Ltd. | Heterocyclic substituted pyrimidine compound |
WO2013067309A1 (en) | 2011-11-04 | 2013-05-10 | Xion Pharmaceutical Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
ES2641992T3 (es) | 2012-08-14 | 2017-11-14 | Xuanzhu Pharma Co., Ltd. | Compuestos de pirimidina bicíclicos sustituidos |
BR112015012420A8 (pt) * | 2012-11-28 | 2017-10-24 | Gruenenthal Gmbh | amino-arilcarboxamidas substituídas como moduladores de kcnq2/3 |
US9248122B2 (en) | 2012-11-28 | 2016-02-02 | Grünenthal GmbH | Heteroquinoline-3-carboxamides as KCNQ2/3 modulators |
WO2014082737A1 (en) | 2012-11-28 | 2014-06-05 | Grunenthal Gmbh | Specific carboxamides as kcnq2/3 modulators |
CN104059025B (zh) * | 2013-03-20 | 2017-07-04 | 广州朗圣药业有限公司 | 一种用于制备阿伐那非的中间体及其制备方法 |
EP2980087B1 (en) * | 2013-03-29 | 2018-06-06 | Xuanzhu Pharma Co., Ltd. | Prodrugs of bicyclic substituted pyrimidine type pde-5 inhibitors |
WO2014174529A2 (en) * | 2013-04-23 | 2014-10-30 | Hetero Research Foundation | Polymorphs of avanafil |
CN103265534B (zh) * | 2013-05-23 | 2014-07-23 | 苏州明锐医药科技有限公司 | 阿伐那非的制备方法 |
CN103254179B (zh) * | 2013-05-23 | 2014-09-10 | 苏州明锐医药科技有限公司 | 阿伐那非的制备方法 |
WO2014187273A1 (zh) * | 2013-05-23 | 2014-11-27 | 苏州明锐医药科技有限公司 | 阿伐那非的制备方法 |
CN103254180B (zh) * | 2013-05-23 | 2014-07-23 | 苏州明锐医药科技有限公司 | 一种阿伐那非的制备方法 |
WO2015001567A1 (en) * | 2013-07-01 | 2015-01-08 | Msn Laboratories Private Limited | Process for the preparation of (s)-4-[(3-chloro-4-methoxybenzyl)amino]-2-[2- (hydroxymethyl)-1-pyrrolidinyl]-n-(2-pyrimidinyl methyl-5-pyrimidine carboxamide |
CN104557877B (zh) * | 2013-10-28 | 2016-08-17 | 重庆安格龙翔医药科技有限公司 | 一种阿伐那非中间体及其制备方法和应用 |
EA201690938A1 (ru) | 2013-11-05 | 2016-11-30 | Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити | Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания |
CN104628707A (zh) * | 2013-11-13 | 2015-05-20 | 北大方正集团有限公司 | 一种阿伐那非的无定型及其制备方法、用途和药物组合物 |
CN104628708A (zh) * | 2013-11-13 | 2015-05-20 | 北大方正集团有限公司 | 一种阿伐那非的晶型及其制备方法、用途和药物组合物 |
CN104650045B (zh) * | 2013-11-19 | 2017-04-19 | 苏州旺山旺水生物医药有限公司 | 阿伐那非的制备方法 |
GB201321748D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
CN103833736A (zh) * | 2014-03-04 | 2014-06-04 | 北京澳合药物研究院有限公司 | 一种阿伐那非的制备方法 |
WO2015177807A1 (en) * | 2014-05-22 | 2015-11-26 | Wanbury Ltd. | A process for the preparation of avanafil and its novel intermediates |
CN104003981A (zh) * | 2014-05-28 | 2014-08-27 | 河北康泰药业有限公司 | 阿伐那非的合成方法 |
CN104151299B (zh) * | 2014-08-22 | 2017-03-08 | 北京科莱博医药开发有限责任公司 | 化合物、晶型化合物及其制备方法 |
CN104356115B (zh) * | 2014-11-21 | 2016-08-24 | 齐鲁天和惠世制药有限公司 | 一种4-[(3-氯-4-甲氧基苄基)氨基]-2-[2-(羟甲基)-1-吡咯烷基]嘧啶-5-羧酸乙酯的制备方法 |
CN104530015B (zh) * | 2014-12-10 | 2017-01-04 | 齐鲁天和惠世制药有限公司 | 一种阿伐那非的制备方法 |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
CN105924402A (zh) * | 2016-05-06 | 2016-09-07 | 蚌埠中实化学技术有限公司 | 一种2-胺基甲基嘧啶盐酸盐的制备方法 |
WO2018011681A1 (en) | 2016-07-14 | 2018-01-18 | Pfizer Inc. | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
CN106496201A (zh) * | 2016-10-31 | 2017-03-15 | 昆药集团股份有限公司 | 一种阿伐那非原料药的制备方法 |
EP3554507A1 (en) | 2016-12-14 | 2019-10-23 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
CN107879986A (zh) * | 2017-12-20 | 2018-04-06 | 重庆英斯凯化工有限公司 | 一种阿伐那非杂质的合成方法 |
CN108658872B (zh) * | 2018-05-03 | 2021-06-22 | 无锡富泽药业有限公司 | 一种阿伐那非中间体的制备方法 |
JP2021533152A (ja) | 2018-08-06 | 2021-12-02 | ニコックス エス.エー. | 一酸化窒素放出性ホスホジエステラーゼ5型阻害薬 |
CN109280049B (zh) * | 2018-09-25 | 2021-02-02 | 重庆奥舍生物化工有限公司 | 一种医药化合物阿伐那非的合成方法 |
CN109776505B (zh) * | 2019-03-14 | 2021-07-27 | 扬州市三药制药有限公司 | 一种阿伐那非的制备方法 |
CN110078713B (zh) * | 2019-04-10 | 2021-06-04 | 北京精华耀邦医药科技有限公司 | 一种用于治疗男性勃起功能障碍的化合物 |
CN110117274A (zh) * | 2019-05-08 | 2019-08-13 | 梯尔希(南京)药物研发有限公司 | 一种阿伐那非杂质的制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1229413A (nl) * | 1967-06-14 | 1971-04-21 | ||
JPS5481299A (en) * | 1977-12-09 | 1979-06-28 | Daito Koeki Kk | Preparation of 2,8-disubstituted-6-formyl-5,8-dihydro-5- oxopyrido 2,3-d pyrimidine derivative |
AT392789B (de) * | 1985-01-23 | 1991-06-10 | Toyama Chemical Co Ltd | Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten |
DE3752141T2 (de) * | 1986-02-24 | 1998-03-26 | Mitsui Petrochemical Ind | Mittel zur behandlung von neuropathie |
DE69115126T2 (de) | 1990-05-16 | 1996-05-09 | Tomoegawa Paper Mfg Co Ltd | Leitfähiges Substrat und seine Verwendung in den Druckmedien. |
GB9012316D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
US5252604A (en) | 1992-07-10 | 1993-10-12 | Hoffmann-La Roche Inc. | Compositions of retinoic acids and tocopherol for prevention of dermatitis |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
ATE163647T1 (de) * | 1993-08-26 | 1998-03-15 | Ono Pharmaceutical Co | 4-aminopyrimidin derivate |
WO1995018097A1 (fr) | 1993-12-27 | 1995-07-06 | Eisai Co., Ltd. | Derive de l'acide anthranilique |
DE69533057T2 (de) | 1994-08-09 | 2005-06-16 | Eisai Co., Ltd. | Kondensierte pyridazinverbindungen |
KR100239800B1 (ko) | 1996-11-28 | 2000-03-02 | 손경식 | 4,5-디아미노 피리미딘 유도체 및 이의 제조방법 |
JP2000072751A (ja) * | 1998-08-26 | 2000-03-07 | Tanabe Seiyaku Co Ltd | イソキノリノン誘導体 |
IL132406A0 (en) | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
GB9823101D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
-
2000
- 2000-09-13 CN CN00812968A patent/CN1374953A/zh active Pending
- 2000-09-13 MY MYPI20004248 patent/MY123528A/en unknown
- 2000-09-13 CN CN2012100068594A patent/CN102584799A/zh active Pending
- 2000-09-13 BR BRPI0014526A patent/BRPI0014526C1/pt not_active IP Right Cessation
- 2000-09-13 DE DE60034239T patent/DE60034239T2/de not_active Expired - Lifetime
- 2000-09-13 KR KR10-2002-7003536A patent/KR100532546B1/ko active IP Right Grant
- 2000-09-13 WO PCT/JP2000/006258 patent/WO2001019802A1/ja active IP Right Grant
- 2000-09-13 EP EP00960979A patent/EP1219609B1/en not_active Expired - Lifetime
- 2000-09-13 IL IL14829100A patent/IL148291A0/xx active IP Right Grant
- 2000-09-13 TW TW089118673A patent/TWI258471B/zh not_active IP Right Cessation
- 2000-09-13 AU AU73118/00A patent/AU767558B2/en active Active
- 2000-09-13 HU HU0202795A patent/HU225917B1/hu active Protection Beyond IP Right Term
- 2000-09-13 ES ES00960979T patent/ES2283315T3/es not_active Expired - Lifetime
- 2000-09-13 AT AT00960979T patent/ATE358670T1/de active
- 2000-09-13 TR TR2002/00701T patent/TR200200701T2/xx unknown
- 2000-09-13 DK DK00960979T patent/DK1219609T3/da active
- 2000-09-13 CA CA002383466A patent/CA2383466C/en not_active Expired - Lifetime
- 2000-09-13 PT PT00960979T patent/PT1219609E/pt unknown
- 2000-09-13 RU RU2002109792A patent/RU2233273C3/ru active Protection Beyond IP Right Term
- 2000-09-14 AR ARP000104829A patent/AR025668A1/es active IP Right Grant
-
2001
- 2001-08-10 US US09/925,892 patent/US6656935B2/en active Active
-
2002
- 2002-02-21 IL IL148291A patent/IL148291A/en unknown
- 2002-03-15 NO NO20021308A patent/NO322038B1/no not_active IP Right Cessation
- 2002-04-02 BG BG106566A patent/BG65453B1/bg unknown
- 2002-08-21 HK HK02106107A patent/HK1044535A1/xx unknown
-
2003
- 2003-05-01 US US10/426,884 patent/US6797709B2/en not_active Expired - Lifetime
-
2007
- 2007-04-20 CY CY20071100542T patent/CY1106534T1/el unknown
-
2013
- 2013-07-10 LU LU92249C patent/LU92249I2/fr unknown
- 2013-07-22 BE BE2013C051C patent/BE2013C051I2/fr unknown
- 2013-08-13 FR FR13C0050C patent/FR13C0050I2/fr active Active
- 2013-09-04 CY CY2013034C patent/CY2013034I2/el unknown
- 2013-12-10 NO NO2013018C patent/NO2013018I2/no unknown